You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 139 No. 4, April 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (17)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Dermatologic Disorders
 •Dermatologic Disorders, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Cutaneous Involvement in Multiple Myeloma

A Clinicopathologic, Immunohistochemical, and Cytogenetic Study of 8 Cases

Luis Requena, MD; Heinz Kutzner, MD; Gabriele Palmedo, PhD; Eduardo Calonje, MD; Celia Requena, MD; Gemma Pérez, MD; María Antonia Pastor, MD; Omar P. Sangueza, MD

Arch Dermatol. 2003;139:475-486.

Background  Specific cutaneous involvement in patients with multiple myeloma (MM) is very uncommon. It usually occurs in late stages of MM as a reflection of increased tumor cell burden. We studied 8 patients with cutaneous involvement of MM without underlying bony lesions and reviewed the literature on this rare dermatologic manifestation.

Design  We were particularly interested in the clinical course of patients with MM and cutaneous metastases, including survival once metastases were detected and the possible influence of various forms of therapy. Our goal was also to identify the immunoglobulin and the light-chain type in these cases, with emphasis on any possible association between a particular immunoglobulin class and cutaneous involvement, as well as the histopathologic, immunohistochemical, and cytogenetic features of the neoplastic plasma cells involving the skin.

Setting  University department of dermatology, university hospital, and private practice.

Patients  Medical records and biopsy specimens from 8 patients with MM and specific cutaneous lesions were reviewed.

Results  Cutaneous lesions consisted of multiple erythematous or violaceous nodules or plaques with a wide anatomical distribution. Histopathologically, 2 different patterns were identified: nodular and diffuse interstitial. Neoplastic plasma cells showed atypical features, and in 1 case they displayed a spindle shape, giving a sarcomatoid appearance to the lesion. Immunohistochemical studies demonstrated that neoplastic plasma cells were strongly positive for CD79a, CD138, and epithelial membrane antigen, and variably positive for VS38c and CD43. In each case the immunoglobulin profile and the light-chain type expression of the neoplastic cells were the same as those identified in the serum of the patients: 5 cases were IgA{lambda}; 2 cases were IgG{kappa}; and 1 case was IgA{kappa}. In cases 2, 3, and 4, polymerase chain reaction investigations revealed monoclonal rearrangement for IgH genes, whereas the investigations for human herpesvirus 8 and Epstein-Barr virus yielded negative results. Fluorescent in situ hybridization investigations in these 3 cases demonstrated that the cutaneous neoplastic plasma cells showed the deletion of the rb-1 (retinoblastoma) gene. Despite aggressive chemotherapy, all 8 patients died a few months after the development of cutaneous involvement.

Conclusions  In our series, there was a perfect correlation of immunoglobulin and light-chain type between the serum electrophoresis and the cutaneous plasma cells. Patients with MM showed a short survival once cutaneous metastases appeared independently of the therapy. The deletion the rb-1 gene may provide prognostically relevant information to identify a high-risk subset of patients with MM.


From the Department of Dermatology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain (Drs L. Requena and Pastor); Dermatopathologische Gemeinschaftspraxis, Friedrichshafen, Germany (Drs Kutzner and Palmedo); Dermatopathology Department, St John's Institute of Dermatology, St Thomas' Hospital, London, England (Dr Calonje); Department of Dermatology, Hospital General Universitario, Valencia, Spain (Drs C. Requena and Pérez); and Departments of Dermatology and Pathology, Wake Forest University, Winston-Salem, NC (Dr Sangueza). The authors have no relevant financial interest in this article.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation
Teng et al.
Ann Rheum Dis 2009;68:1011-1016.
ABSTRACT | FULL TEXT  

Skin Involvement in Immunoglobulin E Multiple Myeloma
Wozney et al.
JCO 2009;27:637-638.
FULL TEXT  

Fistula dysfunction secondary to a subcutaneous myelomatous deposit
Boshell et al.
Nephrol Dial Transplant 2005;20:2827-2829.
FULL TEXT  

Plasma Cell Problems: CASE 1. Disseminated Cutaneous Plasmacytomas Treated With Total Skin Electron Radiotherapy
Floyd et al.
JCO 2005;23:3138-3140.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.